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Nesiritide:  Harmful or Harmless?
Michael P. Dorsch, Pharm.D., and Jo Ellen Rodgers, Pharm.D.
Nesiritide is the recombinant form of human B-type (brain) natriuretic
peptide (BNP), and its amino acid sequence is identical to that of endogenous
human BNP.  Administration of nesiritide results in venous and arterial
vasodilation, as well as enhanced diuresis.  Given the many limitations of
therapies previously available for the treatment of acute decompensated heart
failure, the anticipation was that nesiritide would offer a safer and more
effective therapeutic option.  Recently, two meta-analyses raised the question
of safety with nesiritide therapy, specifically an increased risk of renal
dysfunction and mortality.  Although several studies generated information
regarding the potential role of nesiritide in various settings, the questions
raised by the meta-analyses are concerning.  Our hope is that future clinical
trials will address the concerns raised and provide a better understanding of
the role of nesiritide in the management of acute decompensated heart failure.
Until these data are available, nesiritide use should be limited.
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In the United States, 5 million people currently
have heart failure, with 550,000 new cases
diagnosed each year.  This disease causes consid-
erable morbidity and mortality and is responsible
for a tremendous burden on the health care
system.  The 1-year mortality rate is high, with
one in five patients dying.  In 2003, heart failure
was responsible for more than one million
hospital discharges, an increase of 174% over the
previous two decades.  The indirect and direct
cost of managing this disease state in 2006 is
estimated to be $29.6 billion.1 Inpatient manage-
ment of acute decompensated heart failure
(ADHF) consumes the greatest expenditure for
heart failure care and is associated with an
increased risk of both readmission and subse-
quent death.2
The goals of managing ADHF are different
from those of chronic heart failure, such as
prolonging survival, slowing disease progression,
reducing hospitalization, and improving
symptoms and quality of life.  The goals of
inpatient heart failure care include relieving
pulmonary congestion, decreasing systemic
vascular resistance, and improving myocardial
systolic and diastolic function while preserving
systemic perfusion pressure and optimizing oral
drug therapy.
Limitations of Standard Therapies
Only limited guidance is available for
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practitioners who manage ADHF, with little
consensus on definitions for physiologic and
clinical disease state parameters, and current
guidelines only briefly address management of
this patient population.3 Until recently, the
inpatient management of ADHF was also limited
by the lack of supporting literature and the lack
of development of more sophisticated therapies.
For decades, intravenous loop diuretics and
inotropes have been used as the hallmark of
therapy, the former for fluid overload and the
latter for low cardiac output.  Recent literature
suggests potential drawbacks to these therapies,
including neurohormonal activation and a
potential worsened survival in patients receiving
higher doses of diuretic therapy, and an increased
frequency of adverse effects with inotropic
therapy.4–10
Intravenous furosemide administration has
been associated with a reduction in cardiac
output, which may result in a reduction in renal
blood flow and glomerular filtration rate.4–6
Subsequently, these hemodynamic and renal
effects result in activation of the renin-angio-
tensin-aldosterone system and the sympathetic
nervous system.7, 8 Long-term use of furosemide
further activates these neurohormonal systems
because of relative reductions in intravascular
volume.  Theoretically, further activation of these
negative compensatory systems in heart failure
may result in worse clinical outcomes.  A
retrospective analysis of the Prospective
Randomized Amlodipine Survival Evaluation
(PRAISE) trial data suggested that long-term use
of diuretics can be harmful.9 High diuretic doses
were independently associated with total
mortality, sudden death, and pump failure death
(p<0.05 for all), and the use of metolazone was
an independent predictor of total mortality
(p=0.16).
For many years, inotropic therapy has been
well established to have proarrhythmic potential.
In the Outcomes of a Prospective Trial of
Intravenous Milrinone for Exacerbations of
Chronic Heart Failure (OPTIME-CHF) trial,
intravenous milrinone was associated with
significantly more arrhythmia and hypotension
compared with placebo in patients with ADHF.10
More recently, data from the Acute Decompensated
Heart Failure National Registry (ADHERE)
further support less favorable outcomes, sug-
gesting an increase in mortality with intravenous
inotropic therapies (milrinone and dobutamine)
compared with vasodilator therapies (nesiritide
and nitroglycerin).11
Nesiritide Overview
Nesiritide (Natrecor; Scios, Inc., Fremont, CA)
is the recombinant form of human B-type (brain)
natriuretic peptide (BNP), and its amino acid
sequence is identical to that of endogenous
human BNP.  The agent is indicated for the
intravenous treatment of patients with ADHF
who have dyspnea at rest or with minimal
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Table 1.  Results of the Pivotal Randomized, Controlled, Double-Blind Trials of Nesiritide14–16
No. of Control Nesiritide Dosage
Trial Patients Therapy (bolus, infusion) Primary End Point
NSG14
Efficacy 127 Placebo 0.3-µg bolus + 0.015 µg/kg/min, PCWP at 6 hrs
0.6-µg bolus + 0.03 µg/kg/min,
Comparative 305 Standarda 0.3-µg bolus + 0.015 µg/kg/min, GCS
0.6-µg bolus + 0.03 µg/kg/min Clinical symptoms
(at 6 hrs, 24 hrs, and end of
therapy)
VMAC15 498 Placebob 2.0-µg bolus + 0.01 µg/kg/min x 3 hrs, PCWP and dyspnea at 3 hrs
Nitroglycerin then fixed dose vs adjustable dose (only compared with placebo)
up to 0.03 µg/kg/min




↓ = decreased; ↑ = increased; PCWP = pulmonary capillary wedge pressure; GCS = global clinical status; NS = not significant; NSG = Nesiritide
Study Group; VMAC = Vasodilation in the Management of Acute CHF; PRECEDENT = Prospective Randomized Evaluation of Cardiac Ectopy
with Dobutamine or Natrecor Therapy; PVBs = premature ventricular beats.
aStandard therapy is dobutamine (57%), milrinone (19%), nitroglycerin (18%), dopamine (6%), and amrinone (1%).
bPlacebo for first 3 hrs then randomized again to nesiritide or nitroglycerin.
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activity, primarily patients with fluid overload.12
In this population, nesiritide causes venodilation
and natriuresis that results in reduced pulmonary
pressure and relieves dyspnea.  Nesiritide is
distinct compared with other drugs that have
diuretic properties in that it also causes arterial
vasodilation, which reduces afterload and
indirectly increases cardiac output.13
Three pivotal clinical trials were responsible for
defining the current role of nesiritide in the
management of ADHF; these trials are briefly
summarized in Table 1.14–16 The first of two
large, randomized, controlled trials assessing
symptomatology—the Nesiritide Study Group
(NSG)—compared nesiritide in 432 patients who
were hospitalized for ADHF.14 The trial was
divided into two parts:  the first part, known as
the NSG efficacy trial (127 patients), used a
double-blind, placebo-controlled design of a
nesiritide 6-hour infusion at two dosing schemes;
the second part, known as  the NSG comparative
trial (305 patients), compared standard therapy
(defined as a single intravenous vasoactive agent
routinely used for the short-term management of
ADHF) with two nesiritide groups with the same
dosing as in the efficacy trial.  Among the 102
patients assigned to the standard therapy group,
dobutamine was the most common choice of
drug therapy (57%) followed by milrinone
(19%).  Thus, 82% of patients in the standard
therapy group were receiving inotropic therapy.
The global clinical status and specific symptoms
of heart failure were assessed by the physician
and the patient at baseline and at 6 hours after
treatment in both parts of the trial.
In the second trial, the Vasodilation in the
Management of Acute CHF (VMAC) trial,
nesiritide was compared with another vasodilator,
nitroglycerin, when either therapy was added to
standard of care in patients with ADHF and
symptoms at rest.15 In addition to dyspnea, this
trial identified a second primary end point,
pulmonary capillary wedge pressure.  The third
trial, the Prospective Randomized Evaluation of
Cardiac Ectopy with Dobutamine or Natrecor
Therapy (PRECEDENT) trial, was primarily a
safety trial to compare nesiritide with dobuta-
mine with regard to effects on arrhythmias.16
Recent Controversial Literature
Nesiritide’s Effect on Renal Function
The initial product information provided by
the manufacturer of nesiritide addressed the issue
of worsening renal function as an adverse event
in the clinical trials conducted until that point.12
The product information reported that nesiritide
may affect renal function in susceptible indi-
viduals.  The manufacturer did state that in
patients with severe heart failure whose renal
function may depend on the activity of the renin-
angiotensin-aldosterone system, treatment with
nesiritide may be associated with azotemia.  Also,
the package insert stated that starting nesiritide
at doses higher than 0.01 µg/kg/minute (0.015
and 0.030 µg/kg/min) is associated with an
increased rate of elevated serum creatinine levels
over baseline values compared with standard
therapies.
The effect of BNP intravenous infusions on
renal function has been studied in healthy
volunteers.17–22 Similar studies have been
conducted in patients with heart failure.13, 23–26 In
general, the neuroendocrinologic alterations seen
after the administration of BNP have included
maintenance of or reduction in aldosterone and
renin levels.  In healthy volunteers, BNP appears
to maintain and perhaps even enhance
glomerular filtration rate and maintain renal
blood flow.  It has modest diuretic properties,
with increases in urine sodium excretion and
urine volume.  Although most of these
neurohormonal and renal responses are similar in
patients with heart failure, one group of authors
reported that the effects of BNP in patients with
heart failure appear to be attenuated, with less
enhancement of sodium excretion, compared
with the effects in healthy patients.24 The
authors demonstrated that the absolute increase
in urinary sodium excretion and the absolute
decrease in distal fractional reabsorption of
sodium (as measured by lithium clearance) with
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Table 1.  (continued)
Results p Value
↓ PCWP <0.001
Improvement in both groups: NS
GCS at 6 hrs, 24 hrs, and end of therapy




↑ with dobutamine <0.05
↑ with dobutamine <0.05
↑ with dobutamine <0.05
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BNP were significantly lower in the patients with
heart failure.  No significant changes were noted
in glomerular filtration rate or renal blood flow
between the control group and the patients with
heart failure.  In contrast, another group of
authors found an enhanced response in patients
with heart failure.25 These investigators found
that urinary excretion of sodium was higher in
the patients with heart failure than in the control
subjects.
Among the studies conducted in patients with
heart failure, we know of only one that
investigated the effect of nesiritide, rather than
BNP, on renal function.26 In this study, a
nesiritide 2-µg/kg bolus followed by a 0.01-
µg/kg/minute or a placebo infusion was given for
24 hours, and glomerular filtration rate, renal
blood flow, urine output, and sodium excretion
were assessed in patients with heart failure who
had moderate renal insufficiency.  Nesiritide did
not improve any of these variables in this
population at the end of the 24-hour infusion.
Unfortunately, each of these renal response
studies varies greatly in enrollment criteria,
method used to measure renal response, washout
duration before crossover, and management of
long-term diuretic therapy, which may explain
the discrepancies in outcomes reported.
To gain a better understanding of the effect of
nesiritide on renal function, renal data from the
VMAC trial15 were assessed in a post hoc
analysis.27 The VMAC trial represents approxi-
mately one third of all patients who have been
studied with nesiritide; thus, this was a
reasonable means to address this issue in a
heterogeneous population.  In 60 patients with
renal insufficiency (serum creatinine level > 2.0
mg/dl), the median change in serum creatinine
level from baseline to the last day of treatment
with study drug was -0.2 mg/dl with nesiritide
0.01 µg/kg/minute and -0.1 mg/dl with
nitroglycerin (dosage titrated to effect, p=0.03).
For 209 patients without renal insufficiency, the
median changes in serum creatinine level from
baseline to the last treatment day were the same
for nesiritide and nitroglycerin, 0 and 0 mg/dl,
respectively (p=0.54).
A summary of the mean serum creatinine level
at various time points for nesiritide-treated
patients with and those without renal insuffi-
ciency may be found in Table 2.  Although these
results overall suggest a neutral effect of
nesiritide, results of a recent meta-analysis of
clinical trial data suggest an increased risk of
worsening renal function in patients with
ADHF.28 This meta-analysis identified trials
through United States Food and Drug
Administration (FDA) documents released by the
Cardiovascular and Renal Drug Advisory
Committee, the drug manufacturer, a PubMed
search (limited to clinical trials on humans
published in English through July 2004), and a
manual search of annual meetings of the
American Heart Association, American College of
Cardiology, and Heart Failure Society of America.
Trials were then selected when they fulfilled each
of the following characteristics:  randomized,
double-blind, parallel-group study in patients
with ADHF and in which the effect on serum
creatinine level was reported.  These sources and
criteria revealed five studies included in the
analysis.  In the five studies, 1288 patients were
enrolled and randomized, with 1269 patients
undergoing assessment of renal function.  The
definition of worsening renal function was an
increase in serum creatinine level of more than
0.5 mg/dl, the only renal function measurement
similar among these trials.
Compared with noninotrope-based control
therapy (diuretics and other vasodilators),
nesiritide increased the risk of worsening renal
function at doses of 0.03 µg/kg/minute or less
and 0.015 µg/kg/minute or less (22% vs 15%,
p=0.003, and 23% vs 15%, p=0.012, respectively)
or at any dose (≤ 0.06 µg/kg/min, 22% vs 15%,
p=0.002).  Compared with any control therapy
(noninotrope- and inotrope-based therapies),
nesiritide increased the risk of worsening renal
function at doses of 0.03 µg/kg/minute or less
and 0.015 µg/kg/minute or less (21% vs 15%,
p=0.001, and 21% vs 15%, p=0.006, respectively)
or at any dose (≤ 0.06 µg/kg/min, 21% vs 15%,
p=0.001).  In further analysis, nesiritide
increased the need for medical intervention
compared with control (11.1% vs 4.2%, p=0.03).
However, no significant difference was noted
between the nesiritide and control groups in the
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Table 2.  Vasodilation in the Management of Acute CHF
(VMAC) Trial:  Effect of Nesiritide on Serum Creatinine
Concentration in Patients with and without Renal
Insufficiency27
Serum Creatinine Concentration (mg/dl)
Patients without Patients with
Time Frame Renal Insufficiency Renal Insufficiency
Baseline 1.2 ± 0.3 3.0 ± 1.5
Day 2 1.3 ± 0.5 2.9 ± 1.6
Day 5 1.3 ± 0.4 3.0 ± 1.6
Data are mean ± SD.
Renal insufficiency defined as a serum creatinine level ≥ 2 mg/dl.
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need for dialysis (2.5% vs 2.2%, p=0.71).28
Additional data on the effects of nesiritide dose
on renal function were presented at the recent
Heart Failure Society of America meeting in
2005, subsequent to the publication of the above
meta-analysis.  Two additional post hoc assess-
ments of the VMAC study data were conducted.
Percentages of patients with an increase in serum
creatinine level of more than 0.5 mg/dl at various
time points are represented in Table 3.  In this
patient subgroup, most increases in serum
creatinine level occurred well after discontinu-
ation of study drug.29 Another evaluation
suggested that the risk of serum creatinine level
increases of more than 0.5 mg/dl was not affected
by vasodilator type (nesiritide vs nitroglycerin) in
patients who received low-to moderate doses of
diuretics (20.2% nesiritide, 21% nitroglycerin,
p=0.975) but was significantly increased in
patients who received high-dose diuretics plus
nesiritide (32.9% nesiritide, 21.4% nitroglycerin,
p=0.044).30 Having assessed patients receiving
different doses of nesiritide in five clinical trials
(1222 patients), a third abstract reported that the
manufacturer-recommended starting dosage of
nesiritide, 0.01 µg/kg/minute, did not worsen
renal function compared with control (p=0.17).31
In contrast, higher starting doses did worsen
renal function when compared with controls
(0.015 µg/kg/min, p=0.02, and 0.03 µg/kg/min,
p=0.001) in a dose-dependent fashion (Table 4).
The risk of increase in serum creatinine level
paralleled the rate of symptomatic hypotension;
however, it is unknown if this represents a causal
relationship.
Nesiritide’s Effect on Mortality
No trial has prospectively identified mortality
as a primary end point with nesiritide.  Pooled
data from the manufacturer in the original
product information states that in all controlled
trials combined, the 6-month mortality rates for
nesiritide and active control (including nitro-
glycerin, dobutamine, nitroprusside, milrinone,
amrinone, and dopamine) were 21.5% and
21.7%, respectively.12
A recently published meta-analysis, written by
the same authors as the above meta-analysis28 on
nesiritide effects on renal function, brought the
issue of nesiritide’s effect on mortality to the
forefront.32 The hypothesis was that if nesiritide
worsens renal function, then it may affect
mortality.  This meta-analysis identified trials
through the same mechanism as the above-
described meta-analysis that assessed renal
function.  Trials were then selected when they
fulfilled each of the following characteristics:
randomized, double-blind, parallel group study
of patients with ADHF, nesiritide therapy
administered as a single infusion for at least 6
hours, control therapy did not mandate the use
of positive inotrope therapy, and mortality was
reported during 30 days of follow-up.  Twelve
randomized controlled trials were identified.  Of
these 12, three were excluded because nesiritide
was administered as an intravenous bolus.  Six
trials were excluded because the 30-day mortality
rate was not reported, patients without ADHF
were enrolled, trial design was open label,
inotrope therapy was allowed as a comparator, or
intermittent infusion therapy was mandated.
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Table 3.  Vasodilation in the Management of Acute CHF (VMAC) Trial:  Temporal Characteristics
of Serum Creatinine Concentration Elevations with Nesiritide and Nitroglycerin29
Percentage of Patients with Serum Creatinine
Concentration Increases > 0.5 mg/dl
Nitroglycerin Nesiritide
Group group
Time Frame (n=212) (n=268) p Value
At any time 12 14 0.50
During infusion 1.9 1.5 0.74
< 72 hrs after infusion discontinued 5.2 6.7 0.57
≥ 72 hrs after infusion discontinued 4.7 6.0 0.69
Table 4.  Pooled Analysis from Five Trials of Patients
Treated with Nesiritide Who Had Increases in Serum
Creatinine Concentrations Greater Than 0.5 mg/dl at Any
Time Through Day 3031
Initial Dosage
(µg/kg/min) Odds Ratio (95% CI) p Value
0.01 1.35 (0.88–2.06) 0.17
0.015 1.90 (1.02–3.54) 0.02
0.03 2.58 (1.40–4.74) 0.001
CI = confidence interval.
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The three remaining trials (862 patients) were
the NSG efficacy trial, VMAC trial, and the
Prospective Randomized Outcomes Study of
Acutely Decompensated Congestive Heart Failure
Treated Initially in Outpatients with Nesiritide
(PROACTION) trial.  The data on death rates
were provided either by the FDA review
documents (NSG efficacy trial and VMAC) or by
the trial sponsor (PROACTION).  The crude
mortality rates in the nesiritide and the control
groups were 7.2% and 4.0%, respectively.  The
meta-analysis using a fixed-effects model
revealed no statistically significant difference in
risk of death in the nesiritide groups compared
with the control groups (risk ratio 1.74, 95%
confidence interval [CI] 0.97–3.12, p=0.059).
The adjusted Kaplan-Meier curves of 30-day
mortality showed a similar outcome (hazard ratio
[HR] 1.80, 95% CI 0.98–3.31, p=0.057).  The
authors concluded that nesiritide may possess an
increased risk of mortality compared with
noninotrope control groups.
Since this analysis, two other pieces of data
have become available with respect to nesiritide’s
effect on mortality.  The ADHERE mortality data
were briefly discussed earlier in this review.11
The ADHERE is a multicenter, observational,
open-label, industry-sponsored registry of the
management of patients with ADHF treated in
hospitals in the United States.  The registry
allows any patient given a discharge diagnosis of
heart failure from participating acute care centers
to be included unless heart failure is not the
principal diagnosis or treatment during the
admission or if the medical record cannot be
accessed for administrative reasons.  The first
65,180 patients (October 2001–July 2003) in the
registry from 263 hospitals were reviewed, with
15,230 patients included in this analysis.  In this
database, the in-hospital mortality was compared
for all patients who received intravenous
treatment with nitroglycerin, nesiritide,
milrinone, or dobutamine.  Adjustments in the
statistical analysis were made to account for eight
parameters that are predictors of heart failure in-
hospital mortality (age, systolic and diastolic
blood pressure, blood urea nitrogen level, serum
creatinine level, sodium level, heart rate, and
dyspnea) along with sex and a propensity score,
which was used to produce unbiased estimates of
the treatment effect in observational studies.
Patients receiving dobutamine and those
receiving milrinone had higher in-hospital
mortality rates compared with either nitro-
glycerin- or nesiritide-treated patients (p<0.005;
Table 5).  No significant difference was noted in
in-hospital mortality when comparing nitro-
glycerin- with nesiritide-treated patients
(p=0.58), but patients receiving dobutamine had
a higher in-hospital mortality rate compared with
milrinone-treated patients (p=0.027).
Having recently updated the package labeling,
the manufacturer of nesiritide released 30-day
mortality data that was collected in all controlled
trials.33 These data were made available publicly
in the April 2005 update of nesiritide’s product
information.  From these seven trials, the 30-day
pooled mortality rate was 5.3% in the nesiritide
group and 4.3% in the control group (HR 1.27,
95% CI 0.81–2.01).  One of the controlled trials
was the Follow-up Serial Infusion of Nesiritide
(FUSION I) pilot trial,34 an outpatient study with
serial nesiritide infusions; this trial was removed
to result in a 30-day mortality rate in the
nesiritide group versus the control group of 5.9%
and 4.4%, respectively (HR 1.34, 95% CI
0.84–2.15; Table 6).  Four of these studies
collected 180-day mortality data.  The pooled
data from these four trials suggest that the
nesiritide group and control group had a 180-day
mortality rate of 21.7% and 21.5%, respectively
(HR 1.05, 95% CI 0.81–1.36; Table 7).
Evolving Literature
Outpatient Setting
The FUSION I trial was a pilot study designed
to assess safety and tolerability of nesiritide in the
outpatient setting.34 Patients with New York
Heart Association (NYHA) functional class III or
IV for at least 60 days before randomization, a 6-
minute walk test less than 400 meters, and at
least two hospital admissions for ADHF (or an
unscheduled outpatient visit requiring therapy
with vasoactive drug) within the past 12 months
were enrolled.  At least one of the hospital
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Table 5.  Acute Decompensated Heart Failure National
Registry (ADHERE):  Nesiritide versus Nitroglycerin and
Inotrope Mortality Data11
Pair-Wise
Treatment Comparisons Odds Ratioa 95% CI
Nitroglycerin vs milrinone 0.69 0.53–0.89
Nitroglycerin vs dobutamine 0.46 0.37–0.57
Nesiritide vs milrinone 0.59 0.48–0.73
Nesiritide vs dobutamine 0.47 0.39–0.56
Nesiritide vs nitroglycerin 0.94 0.77–1.16
Dobutamine vs milrinone 1.24 1.03–1.55
CI = confidence interval.
aAdjusted for covariates and propensity score.
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admissions or unscheduled visits should have
occurred within 5–30 days of enrollment.  After
an intravenous bolus, two nesiritide doses, 0.005
µg/kg/minute (72 patients) and 0.01 µg/kg/minute
(69 patients) for 4–6 hours, were compared with
standard care (69 patients).  Although inotropic
therapy was not allowed in the nesiritide
treatment groups, inotropes were permitted in
the standard care group.  Nesiritide frequency
was determined by the primary investigator but
was a minimum of every other week and a
maximum of twice/week.  Duration of therapy
was 12 weeks, and the study assessed safety and
tolerability through investigator reporting of
adverse events and study drug discontinuation
due to adverse events.  Nesiritide was adminis-
tered on 1645 occasions, and 11 discontinuations
(< 1%) due to adverse events occurred.  No
increase in the frequency of adverse events
occurred in either the nesiritide or the standard
care group.  Nesiritide was discontinued in four
patients (6%) receiving 0.005 µg/kg/minute and
five patients (7%) receiving 0.01 µg/kg/minute.
Several secondary clinical end points were
assessed (Table 8).  No significant difference was
noted in death (7/69 [10%] vs 9/141 [6%],
p=0.314) or all-cause hospitalization (37/69
[54%] vs 65/141 [46%], p=0.378) in the standard
care group versus the combined nesiritide
groups.  There was a trend toward an increase in
days alive and out of the hospital in nesiritide-
treated patients.  The investigators concluded
that outpatient administration was safe and that
additional studies were necessary to determine
effect on morbidity and mortality in the
outpatient setting.  The greatest limitation of this
trial was that inotropic therapy was allowed in
the standard care group, specifically 40 patients
(58%) in the standard care group received
intravenous inotropic therapy. Without a placebo
control group, only conclusions with respect to
nesiritide compared with inotrope can be made.
The FUSION II trial was designed to further
assess the safety and efficacy of serial infusions of
outpatient nesiritide.35 Two dosing frequencies
will be assessed, once/week and twice/week, in
this placebo-controlled trial.  Patients will be
treated for 3 months and, in a blinded follow-up
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Table 6.  All Nesiritide Controlled Trials with 30-Day Mortality Data33
No. (%) of Patients Hazard Ratio
Trial Nesiritide Group Control Group (95% CI)
Mills et al 2/74 (2.7) 2/29 (7.5) 0.38 (0.05–2.67)
NSG efficacy 5/85 (5.9) 2/42 (4.8) 1.25 (0.24–6.45)
NSG comparative 14/203 (6.9) 5/102 (4.9) 1.43 (0.52–3.97)
PRECEDENT 6/163 (3.7) 5/83 (6.1) 0.6 (0.18–1.97)
VMAC 22/273 (8.1) 11/216 (5.1) 1.56 (0.75–3.24)
PROACTION 5/120 (4.2) 1/117 (0.9) 4.99 (0.58–42.73)
FUSION I 2/141 (1.4) 2/69 (2.9) 0.49 (0.07–3.47)
Pooled (6 studies)a 54/918 (5.9) 26/589 (4.4) 1.34 (0.84–2.15)
Pooled (7 studies) 56/1059 (5.3) 28/658 (4.3) 1.27 (0.81–2.01)
CI = confidence interval; NSG = Nesiritide Study Group; PRECEDENT = Prospective Randomized Evaluation of
Cardiac Ectopy with Dobutamine or Natrecor Therapy; VMAC = Vasodilation in the Management of Acute CHF;
PROACTION = Prospective Randomized Outcomes Study of Acutely Decompensated Heart Failure Treated
Initially as Outpatients with Nesiritide; FUSION = Follow-up Serial Infusion of Nesiritide.
aData without FUSION I trial.
Table 7.  All Nesiritide Controlled Trials with 180-day Mortality Data33
No. (%) of Patients Hazard Ratio
Trial Nesiritide Group Control Group (95% CI)
NSG efficacy 19/85 (23.1) 8/42 (19.3) 1.25 (0.55–2.85)
NSG comparative 42/203 (20.8) 24/102 (23.5) 0.88 (0.53–1.45)
PRECEDENT 26/163 (16.3) 18/83 (22.2) 0.74 (0.40–1.34)
VMAC 67/273 (25.1) 44/216 (20.8) 1.22 (0.83–1.79)
Four studies pooled 154/724 (21.7) 94/443 (21.5) 1.05 (0.81–1.36)
CI = confidence interval; NSG = Nesiritide Study Group; PRECEDENT = Prospective Randomized Evaluation of
Cardiac Ectopy with Dobutamine or Natrecor Therapy; VMAC = Vasodilation in the Management of Acute CHF.
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period, will be followed for an additional 3
months.  Standard care will be allowed in all
treatment arms.  It is anticipated that 300
patients will be randomly assigned to each of the
two nesiritide arms and 150 patients will be
enrolled to each of the two placebo arms.  For
efficacy, a combined end point of mortality and
cardiorenal rehospitalization will be assessed.
Patient enrollment is complete.
Emergency Department or Observational Unit
The PROACTION Trial was a pilot study to
assess the safety and efficacy of nesiritide in
patients with ADHF who were being managed in
the emergency department.36 This multicenter,
double-blind, placebo-controlled study enrolled
patients who came to the emergency department
with ADHF, defined as heart failure causing
dyspnea at rest or with minimal activity and
requiring intravenous therapy for at least 12
hours.  Patients received a nesiritide 2-µg/kg
bolus followed by a 0.01-µg/kg/minute or
placebo infusion for at least 12 hours.  Patients
were allowed to receive standard care with the
following exceptions:  oral angiotensin-
converting enzyme (ACE) inhibitors were not
allowed from 2 hours before until 30 minutes
after start of study drug, and intravenous
dopamine, dobutamine, milrinone, b-blockers,
ACE inhibitors, nitroglycerin, and nitroprusside
were not allowed from 2 hours before until 3
hours after start of study drug.  Patients were not
enrolled if it was anticipated that they could not
be discharged from the emergency department or
observation unit in less than 24 hours.  This
study reported the effect of nesiritide on systolic
and diastolic blood pressure, heart rate, and
occurrence of hypotension.  Among the 237
patients enrolled (120 in the nesiritide group,
117 in the placebo group), no significant
differences were noted in baseline characteristics
or concomitant drug administration during the
12-hour treatment phase between the two
treatment groups.
Only 60% of patients enrolled were NYHA
class III or IV, and only 6% had systolic blood
pressures below 101 mm Hg, suggesting a
population with less severe heart failure.  During
the 12-hour treatment phase, no significant
difference was noted in overall blood pressure
between the two treatment groups.  At 6 hours,
nesiritide significantly reduced both systolic (by
13 vs 4 mm Hg, p<0.001) and diastolic (by 6 vs 0
mm Hg, p=0.002) blood pressure, compared with
placebo.  At 12 hours, nesiritide significantly
reduced both systolic (by 17 vs 6 mm Hg,
p<0.001) and diastolic (by 7 vs 1 mm Hg,
p=0.003) blood pressure compared with placebo.
The reduction in systolic blood pressure with
nesiritide was proportional to baseline systolic
blood pressure.  Heart rate was slightly reduced
in both treatment groups, with no significant
differences except at 6 hours (4.1 vs -0.8
beats/min nesiritide vs placebo, p=0.029).  There
were no significant differences in the rate of
symptomatic or asymptomatic hypotension
between the two groups.  Complaints of headache
or leg cramps were also similar between the two
treatment groups.  The authors concluded that
nesiritide was safe and effective at reducing blood
pressure, which may serve as a reasonable
surrogate for afterload reduction in the absence
of invasive hemodynamics.
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Table 8.  Follow-up Serial Infusion of Nesiritide (FUSION) I Trial34
Nesiritide Nesiritide All
Safety and Other Standard Care 0.005 µg/kg/min 0.01 µg/kg/min Nesiritide
Clinical Outcomes (n=69) (n=72) (n=69) (n=141)
No. (%) of Patients
Primary end point
Infusion terminated due NA 4 (6) 5 (7) 9 (6)
to adverse events
Secondary end pointsa
Death 7 (10) 6 (8), p=0.692 3 (4), p=0.194 9 (6), p=0.314
All-cause hospitalization 37 (54) 32 (44), p=0.314 33 (48), p=0.610 65 (46), p=0.378
Mean ± SD
Days alive and out of hospital 74 ± 18 76 ± 15, p=0.253 79 ± 11, p=0.159 78 ± 13, p=0.131
NA = not applicable.
aAll p values indicate no significant difference between each nesiritide group and the standard care group.
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From these same investigators, an abstract with
additional outcome data was presented at the
American College of Cardiology meeting in
Spring 2003.37 The investigators refer to 250
patients with decompensated heart failure who
were randomly assigned to receive nesiritide or
placebo for at least 12 hours.  From the
emergency department, nesiritide-treated patients
were less likely to be admitted (49% vs 55%) and
less likely to be admitted for heart failure (30% vs
38%) than those in the placebo group (no p value
reported).  Of the patients who did require
hospitalization, nesiritide-treated patients had a
lower 30-day rehospitalization rate (10% vs 23%,
p=0.058) and a lower 30-day length of stay
(includes initial visit and rehospitalization, 5.5 vs
10.2 days, p=0.052) than the placebo group.  The
overall cost was lower in patients treated with
nesiritide, primarily due to a reduction in length
of stay and rehospitalization.  The authors did
not include these results in the above publication
of this study36 nor have they published these
results separately.
Most recently, in January 2006, the manu-
facturer of nesiritide reported two additional
deaths of patients who were enrolled in the
PROACTION study.35 These deaths occurred
within 30 days after treatment with nesiritide and
were not previously reported in the original
PROACTION trial report to the FDA.  Inclusion
of these deaths into the overall number of deaths
that have occurred with nesiritide compared with
control would be a mortality rate of 5.5% and
4.3%, respectively.  Since PROACTION was
included in the mortality meta-analysis, how
these two additional deaths would influence the
30-day mortality results is unknown.
An analysis of ADHERE data assessed the effect
of beginning vasoactive therapy in the emergency
department on outcomes.38 At the time of
analysis, ADHERE contained data from 265 acute
care hospitals.  The investigators assessed
patients admitted through the emergency
department between October 2001 and July 2003
who had received nesiritide but no other intra-
venous vasoactive drug.  Patients who received
nesiritide in the emergency department (803
patients) were compared with those who received
nesiritide after admission (1223 patients).
Median time to start of nesiritide therapy was
shorter in patients treated in the emergency
department (2.7 vs 18.3 hrs, p<0.0001) and
median length of stay was also reduced (4.1 vs
5.7 days, p<0.0001) compared with those treated
after admission.  Patients in whom therapy was
delayed were more likely to require transfer to
the intensive care unit and to have a prolonged
length of stay (9% vs 2% and 35% vs 19%,
p<0.0001).  The authors concluded that early
start of nesiritide resulted in better patient
outcomes.  Study results have been published
only as an abstract at this time.
Reducing Length of Stay and Cost
One group of authors retrospectively assessed
the data of 129 consecutive admissions to the
coronary care unit in 98 patients with a diagnosis
of heart failure.39 Patients receiving nesiritide
(58 patients) were compared with patients who
did not receive nesiritide (71 patients).  Overall,
the nesiritide-treated patients appeared to have
more severe heart failure with a lower baseline
ejection fraction and systolic blood pressure, a
higher serum creatinine level, and longer QRS
duration.  Despite this suggestion of an increased
severity of illness and no significant change in
weight or renal function, nesiritide-treated
patients had a significantly shorter length of stay
(p=0.002; Table 9) compared with those not
receiving nesiritide, and multiple linear
regression analysis indicated that length of stay
was significantly related to nesiritide use
(p=0.001).  The authors concluded that nesiritide
may facilitate early discharge of patients without
harming renal function.  Data from ADHERE
have demonstrated that lower systolic blood
pressure and a higher blood urea nitrogen and
serum creatinine level on presentation to the
hospital are indeed associated with an increase in
mortality, so the conclusion by authors that
nesiritide-treated patients had greater severity of
disease seems reasonable.40 However, given the
retrospective nature of this study design, the lack
of other important baseline differences between
the two treatment groups cannot be established
and differences in patient management with
other ADHF therapies cannot be determined as
not having influenced the study outcome.
Results of the NSG trial and the PRECEDENT
trial are described in Table 1.  One group of
authors retrospectively combined the data for
nesiritide- and dobutamine-treated patients from
the NSG comparative and PRECEDENT trials to
assess nesiritide’s effects on length of treatment
and length of stay as well as mortality.41 No
significant differences were noted in the baseline
characteristics or hemodynamics between
treatment groups with the exception of the
following:  history of myocardial infarction and
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ischemia as causes of heart failure was greater in
the dobutamine group, whereas fewer patients
receiving nesiritide 0.015 µg/kg/minute were
white or had a history of sudden death and more
patients receiving nesiritide 0.03 µg/kg/minute
had a history of sustained ventricular tachycardia.
The investigators reported a shorter total
duration of administration (p<0.001) and shorter
total duration of all intravenous vasoactive
therapy (p≤0.012) with nesiritide 0.015 µg/kg/
minute as well as nesiritide 0.03 µg/kg/minute
compared with dobutamine.  Although no
significant difference was noted in median length
of stay between the nesiritide- and dobutamine-
treated patients, a trend existed for fewer all-
cause readmissions at 21 days with both
nesiritide groups (8% nesiritide 0.015 µg/kg/min
and 11% nesiritide 0.03 µg/kg/min vs 20%
dobutamine, overall p<0.05, low-dose nesiritide
p=0.085) and a significantly lower mortality at 6
months in the lower dose nesiritide group (18%
nesiritide 0.015 µg/kg/min and 24% nesiritide
0.03 µg/kg/min vs 31% dobutamine, overall
p<0.05, low-dose nesiritide p=0.123).  The
primary limitation of this study was the
retrospective nature of the assessment as well as
the comparison with dobutamine rather than
placebo.  The possibility that confounding by
indication did not occur with dobutamine-treated
patients having more severe underlying disease
cannot be eliminated.
Both of the above retrospective studies can be
compared with that of the VMAC trial in which
nesiritide-treated patients had a longer length of
stay (10 vs 8 days, p=0.08) compared with
nitroglycerin-treated patients.35
Another group of authors combined the results
of the NSG comparative trial and PRECEDENT
trial to study the economic implications of
nesiritide compared with dobutamine.42 Cost of
medical care was determined by the Monte Carlo
simulation to estimate treatment cost and survival
in hypothetical cohorts (1000 patients/treatment
group) since neither trial recorded charges or
resource utilization.  Only events that were both
clinically significant and likely to generate use of
additional medical resources were identified.  For
example, symptomatic hypotension was
included, whereas asymptomatic hypotension
was not.  Of importance, patients receiving
nesiritide 0.03 µg/kg/minute were excluded.  The
simulation suggested that despite a higher
acquisition cost, nesiritide was associated with
less resource utilization during the initial hospital
stay as well as a lower readmission rate at 21
days, which resulted in a cost neutral end result
(Table 10).  The authors also suggested a survival
advantage.  The primary limitation of this study
was the comparison with dobutamine rather than
placebo.  It is important to mention again that all
patients receiving nesiritide 0.03 µg/kg/minute
were excluded from the simulation, which could
have influenced the outcome of the study given
that higher nesiritide doses are associated with
greater adverse effects.  In addition, this economic
evaluation did not account for selection bias with
dobutamine-treated patients and uncertainty in
21-day heart failure readmission and 6-month
mortality estimates.
Given the limitations of the above economic
evaluation,42 another group performed an
economic analysis of the only randomized
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Assessment (n=58) (n=72) p Value
Baseline parameters
Systolic blood pressure (mm Hg) 116 ± 23 129 ± 29 0.0126
Ejection fraction (%) 20 ± 14 32 ± 24 0.0156
QRS duration (msec) 150 ± 42 128 ± 39 0.0084
Sodium level (mEq/L) 136 ± 5 137 ± 6 0.3375
Blood urea nitrogen level (mg/dl) 44 ± 30 37 ± 24 0.1897
Serum creatinine level (mg/dl) 1.80 ± 0.87 1.52 ± 0.89 0.1163
Outcomes from admission to discharge
Change in blood urea nitrogen level (mg/dl) -1.9 ± 13.3 -1.3 ± 13.5 0.8043
Change in serum creatinine level (mg/dl) -0.11 ± 0.55 -0.07 ± 0.38 0.6348
Change in weight (lbs/day) -2.83 ± 1.91 -2.33 ± 2.22 0.1981
Length of stay (days) 3.91 ± 1.3 4.77 ± 1.7 0.0023
Data are mean ± SD.
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comparison with dobutamine, the PRECEDENT
trial, and these authors used multiple methods of
probabilistic sensitivity analysis.43 Monte Carlo
analysis was used to create results for three
scenarios:  best-case nesiritide, best-case
dobutamine, and a full probabilistic analysis.
The two best-case analyses took into consideration
95% CIs for 21-day heart failure readmission and
6-month mortality.  In addition, the analysis
performed by the previously mentioned group42
was reproduced.  When the uncertainty around
point estimates for readmission and mortality
were included, either nesiritide or dobutamine
could be proved as the dominant therapy (greater
efficacy with lower cost).  Overall, these investi-
gators found that nesiritide did not provide
robust economic benefit over dobutamine.  The
investigators did acknowledge the limitations of
their study design.  More important, they
appropriately questioned the comparison of
nesiritide with dobutamine given that the two
therapies are routinely used in different heart
failure subpopulations.
More recently, a retrospective cohort study
analyzed the outcomes associated with vasoactive
therapy in ADHF.44 The authors reviewed
information from the University HealthSystem
Consortium clinical database, which contains
data from 32 academic institutions, and
categorized patients according to the vasoactive
therapy received.  Length of stay, total health care
costs, and in-hospital mortality rate were
assessed.  In-hospital and intensive care unit
mean length of stay were significantly shorter in
nesiritide-treated patients (7.0 and 1.1 days,
respectively) compared with both milrinone
(12.2 and 3.9 days, respectively) and dobutamine
(10.4 and 3.5 days, respectively) (p<0.001 for all
comparisons).  Mean total health care costs were
lower in nesiritide-treated patients ($18,517)
compared with milrinone ($29,507; p<0.001),
but not significantly lower than dobutamine
($23,116).  The in-hospital mortality rate was
significantly higher in the milrinone (7.9%) and
dobutamine (10.2%) group compared with the
nesiritide group (2.9%; p<0.001), even after
adjustment for baseline variables.
Although this study shows some interesting
results, there are some criticisms in the design.44
Not only was the study retrospective with a
potential selection bias, but the baseline charac-
teristics were not matched optimally. As stated
previously, data from the ADHERE registry
demonstrated that low systolic blood pressure,
and high blood urea nitrogen and serum
creatinine levels in patients presenting to the
hospital are associated with an increase in in-
hospital mortality,40 but none of these baseline
characteristics were reported or controlled for in
this analysis.44 These data then lead to unclear
conclusions of how nesiritide fits into the
management of ADHF.
Discussion
The questions raised by the studies reviewed in
this article are thought provoking and generate
several research hypotheses that need to be
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Clinical event (n=188) (n=144) p Value
Cardiac arrest 2.7 3.6 0.746
Symptomatic hypotension 17.1 5.7 0.000
Readmission for heart failure 4 9.4 0.030
6-mo mortality 16 25 0.030
Mean ± SE
Cost model result (n=1000) (n=1000) Differencea
Cost at initial admission
Without study drug cost $10,969 ± 72 $11,091 ± 80 $-122 ± 91
With study drug cost $11,729 ± 72 $11,127 ± 80 $602 ± 91
Cost of readmission for heart
failure $345 ± 57 $1029 ± 99 $-686 ± 114
Cost of treatment episodeb $12,074 ± 93 $12,156 ± 129 $-83 ± 145
aDifference is nesiritide cost minus dobutamine cost.
bInitial admission plus readmission for heart failure.
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addressed.  Unfortunately, the limitations of the
design of these studies allow one to question the
results, as the data were generated from retro-
spective observations, meta-analyses, pooled
analyses, abstracts, and industry-sponsored
registries.  Future studies should address the role
of nesiritide in reducing hospital length of stay
and cost, as well as in preventing hospital
admission.  Nesiritide’s effect on renal function
and mortality should be closely examined.  In
addition, efficacy and safety needs to be assured
in various heart failure subpopulations.
The effect of nesiritide on renal function and
mortality are critically important as it currently
remains unknown if the use of nesiritide in heart
failure has the potential for long-term harm or
benefit.  One could propose that, as with diuretic
therapy, reductions in intravascular volume may
occur with nesiritide and be responsible for
adverse renal effects.  Hypotension associated
with significant reductions in vascular tone could
worsen renal perfusion as well.
Interrelated, the overall response to nesiritide
may vary greatly depending on the heart failure
subpopulation assessed.  For example, patients
with volume-dependent low cardiac output are
less apt to tolerate large shifts in fluid.  Also,
patients with low systemic vascular resistance
will likely not tolerate significant arterial
vasodilation.  Perhaps this agent could be more
safely and effectively administered to a select
subpopulation of patients with heart failure by
using more patient-specific dosing recommen-
dations.
In addition, the effect of nesiritide on hospital
length of stay and readmission is equally
important, as hospitalization is the primary
determinant of cost associated with management
of heart failure.  Despite the high acquisition cost
associated with nesiritide, if hospital stay or
readmission were reduced significantly with its
use, it may be a cost-effective therapy.  Without
further study, the effect of nesiritide on any of the
above end points remains unknown.  Several
clinical trials with nesiritide are ongoing (Table
11).  We hope future clinical trials will address
the questions raised by the retrospective studies
and meta-analyses and provide a better under-
standing of the role of nesiritide in the manage-
ment of ADHF and the various subpopulations
within this disease state.  Until additional data
are available, nesiritide use should be limited to
the patient population studied and for the
purposes for which it has been demonstrated to
be beneficial.
Conclusion
At this time, the literature supports nesiritide
use in patients who come to the hospital with
ADHF and dyspnea at rest or with minimal
activity for the purpose of rapid symptom
control.  As suggested in the product labeling,
nesiritide should be started at 0.01 µg/kg/minute.
Nesiritide should be avoided in patients with
cardiogenic shock and systolic blood pressure
below 90 mm Hg.  Because of dose-related
hypotension and renal dysfunction, upward
titration of the dosage should be minimized.
Given the significant morbidity and mortality
associated with ADHF and the substantial
economic impact of this disease, the need for
additional therapies and clinical trials supporting
these therapies is warranted.  Until such studies
are conducted, the ADHF population will
continue to be managed with the currently
available therapies, which are hindered by limited
efficacy and adverse effects.  Practitioners caring
for these patients will remain hopeful that new
therapies and supporting literature will be
generated in a timely fashion.
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